Literature DB >> 25708607

The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia by primary care family physicians in Portugal.

Júlio Fonseca1, Carlos Martins da Silva.   

Abstract

BACKGROUND: The shift towards primarily pharmacological management of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) has led to an increasing proportion of patients being treated in the primary care setting.
METHOD: Two related studies were undertaken in Portugal. The first was a survey of primary care family physicians regarding the management of LUTS/BPH. The second was a cross-sectional study of the records of patients with suspected or confirmed LUTS/BPH managed by the surveyed physicians.
RESULTS: One hundred and sixty-three physicians were surveyed between 16 June 2012 and 10 February 2013 and 2,988 patients were identified (mean age 68 years). While 80 % of physicians would order diagnostic tests for patients reporting symptoms, only 2.5 % would initiate treatment based on reported symptoms alone. Only 1 % would refer patients directly to a urologist for diagnosis, and 75 % would only refer patients after an inadequate response to treatment in the primary care setting. Management practices varied according to physicians' age and experience. Nocturia was both the most common and the most bothersome symptom. Erectile dysfunction was reported by 51 % of patients and 81 % had hypertension, hypercholesterolaemia and/or diabetes mellitus. Diagnosis and treatment of LUTS/BPH differed for older patients, those with comorbidities and those with more severe nocturia at presentation.
CONCLUSION: Primary care physicians in Portugal usually diagnose and treat patients with LUTS/BPH rather than refer them to a urologist. Physicians' age and experience, and patients' age, comorbidities and symptom severity affect the management of LUTS/BPH in primary care in Portugal.

Entities:  

Mesh:

Year:  2015        PMID: 25708607     DOI: 10.1007/s40261-014-0256-4

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  16 in total

1.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

Review 2.  Intrinsic and extrinsic factors controlling benign prostatic growth.

Authors:  C Lee; J M Kozlowski; J T Grayhack
Journal:  Prostate       Date:  1997-05-01       Impact factor: 4.104

3.  Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK.

Authors:  P Trueman; S C Hood; U S Nayak; M F Mrazek
Journal:  BJU Int       Date:  1999-03       Impact factor: 5.588

4.  Characteristics of patients presenting with LUTS/BPH in six European countries.

Authors:  Annie Hutchison; Richard Farmer; Christopher Chapple; Richard Berges; Ludger Pientka; Pierre Teillac; Andrzej Borkowski; Piotr Dobronski
Journal:  Eur Urol       Date:  2006-05-19       Impact factor: 20.096

5.  Urologic diseases in America project: benign prostatic hyperplasia.

Authors:  John T Wei; Elizabeth Calhoun; Steven J Jacobsen
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

Review 6.  Established medical therapy for benign prostatic hyperplasia.

Authors:  Gregory B Auffenberg; Brian T Helfand; Kevin T McVary
Journal:  Urol Clin North Am       Date:  2009-11       Impact factor: 2.241

7.  Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older.

Authors:  Matthias Oelke; Birgitt Wiese; Richard Berges
Journal:  World J Urol       Date:  2014-08-08       Impact factor: 4.226

8.  Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

Authors:  Raymond Rosen; Jens Altwein; Peter Boyle; Roger S Kirby; B Lukacs; Eric Meuleman; Michael P O'Leary; Paolo Puppo; Chris Robertson; Francois Giuliano
Journal:  Eur Urol       Date:  2003-12       Impact factor: 20.096

9.  Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors.

Authors:  J Kellogg Parsons
Journal:  Curr Bladder Dysfunct Rep       Date:  2010-09-07

10.  Therapeutic options in the treatment of benign prostatic hyperplasia.

Authors:  Jaspreet S Sandhu
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more
  1 in total

1.  Latest developments in the assessment and treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what is clinically relevant?

Authors:  Matthias Oelke
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.